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Abstract
Background: Pyoderma Gangrenosum (PG) is a cutaneous condition, its diagnosis suggested by the presence of a
painful cutaneous ulcer showing rapid progression. Pyoderma gangrenosum is associated with a concomitant systemic
disease in 50 to 70 % of cases, including inflammatory bowel disease (IBD), rheumatoid arthritis, and lymphoproliferative
disorders. Although PG has also been reported with viral hepatitis, it is rarely associated with autoimmune hepatitis.
Case presentation: A 19-year-old Caucasian female, with a prior diagnosis of autoimmune hepatitis (AIH) in remission,
presented with bilateral lower limb ulcers 4 years after the diagnosis of AIH. She was diagnosed with PG and treated
with high-dose prednisolone, methotrexate and cyclosporine. One year later she was well, the ulcers completely healed,
and with the autoimmune hepatitis still in remission.
Conclusion: We report a case of autoimmune hepatitis and the subsequent, rarely occurring, extra-hepatic onset of
pyoderma gangrenosum, with the AIH in remission, strengthening the association between the two conditions. Since
both the AIH and the PG can present serious diagnostic challenges, thus delaying vital therapy, it is important that the
development of either prompts us to consider the possibility of the other developing in the future or if already present
facilitate its diagnosis, such considerations making the case for a systematic follow up.
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Background
Pyoderma Gangrenosum (PG), classified as a neutro-
philic dermatosis, is an ulcerative cutaneous condition,
first described in 1930 by Brusting and colleagues [1, 2].
Commonly, the lesions present as tender pustules that
evolve into enlarging suppurative ulcers, with a tendency
to last for months or years.
Although of non-infectious etiology, the pathogenesis of
the disease is unclear, but evidence suggests an underlying
defective neutrophilic function [1, 3]. After excluding
more common causes of cutaneous ulcerations, the diag-
nosis of PG is suggested by the presence of a painful,
necrolytic cutaneous ulcer, with an irregular undermined
border, showing rapid progression [1]. Histologically, there
is lymphocytic infiltration in the early stages followed by
neutrophilic infiltration and hemorrhage [4, 5]. Pyoderma
gangrenosum is associated with a concomitant disease in
50 to 70 % of cases, including inflammatory bowel disease
(IBD) in 10 to 15 % [6], rheumatoid arthritis [7], and lym-
phoproliferative disorders [8–10]. Although PG has been
encountered with viral hepatitis [11], only a small number
of cases have been reported with autoimmune hepatitis
(AIH) [12–15]—one associated with concurrent primary
sclerosing cholangitis and ulcerative colitis [13].
Treatment of PG is non-surgical and consists of a
combination of local wound care and systemic therapy,
the latter centered on the use of high-dose corticoste-
roids [16]. Other treatment agents include immunosup-
pressants, intravenous immunoglobulin, and biologic
agents—such as tumor necrosis factor alpha inhibitors
[16]. We report a 19-year-old patient, with a history of
AIH in remission, who presented with pyoderma gang-
renosum of the lower extremities, and was treated suc-
cessfully with cortisone, cyclosporine and methotrexate.* Correspondence: T_Androutsakos@yahoo.gr
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A 19-year-old Caucasian female presented to us with bilat-
eral lower limb ulcers. She reported a scratch on her left
ankle 3 months earlier that worsened over time into an
ulcer, in spite of antibiotic treatment. A week later, new
lesions appeared on the left leg and similar ones were seen
on her right leg. The patient denied fever, weight loss, or
other signs or symptoms of systemic illness. Four years
earlier she had been admitted at another hospital with
transaminasemia and jaundice and was diagnosed with
autoimmune hepatitis based on serological (ANA and
ASMA) positivity and compatible histopathological fea-
tures, in the absence of viral markers. Treatment with
prednisolone and azathioprine brought the disease into
remission. The patient was on 5 mg prednisolone upon
presentation.
On admission, the patient was afebrile, bearing purulent,
painful ulcers in both legs (Fig. 1a). Lab results showed
the inflammation markers just exceeding the upper nor-
mal limits (Table 1). Transaminases were within a normal
range, while anti-nuclear antibodies (ANA) were positive
at a titer of 1/320 and anti-smooth muscle antibodies
(ASMA) were positive at a low titer (1/80). Cryoglobulin
test was negative. The lesions were cultured for bacteria
and Mycobacterium tuberculosis, and empiric therapy
was started with clindamycin and moxifloxacin. Magnetic
Resonance Imaging (MRI) of the region of ulcers in both
legs revealed diffuse subcutaneous oedema and subcuta-
neous nodular lesions on the dorsal surface of the feet.
With a working diagnosis of pyoderma gangrenosum, a
skin biopsy was acquired, her previous medication of
azathioprine was reintroduced at 150 mg, while the ste-
roids were increased from 5 to 20 mg prednisolone, daily.
The patient was discharged pending the pathology and
bacteriology results.
She returned a week later with arthritis of both ankles
and worsening of the ulcers (Fig. 1b). Further cultures were
again negative. The biopsy was interpreted as being com-
patible with pyoderma gangrenosum (Fig. 2a, b), hence
prednisolone 1 mg/kg was started, azathioprine was
switched to cyclosporine at 150 mg that was further
increased to 250 mg daily, and methotrexate 10 mg/week
was added to the regimen. Given the rare combination of
pyoderma gangrenosum with autoimmune hepatitis, upper
and lower endoscopies, as well as upper abdominal
MRI and Magnetic Resonance Cholangio-pancreatography
(MRCP) were done to exclude more common associated
diseases. All of the investigations were negative. A review
of the initial liver biopsies confirmed the diagnosis of auto-
immune hepatitis, showing dense portal and periportal
lymphocytic and plasmacytic infiltrates, as well as mild
periportal fibrosis. The patient was again discharged, with
slow tapering of the steroids.
On follow up a month later she was feeling well, with no
ankle swelling, and with all ulcers healing satisfactorily
(Fig. 1c). Six months hence she was on 4 mg methylpred-
nisolone, 100 mg cyclosporine, and 7.5 mg methotrexate,
with normal liver enzymes, and with the ulcers nearly
healed (Fig. 1d). Cyclosporine was discontinued at
8 months, and a year later the patients was on 4 mg
methylprednisolone and 7.5 mg methotrexate, with
further improvement and complete healing of the ul-
cers (Fig. 1e).
Fig. 1 Images of ulcerated areas. a On admission. b A week later. The swelling and the inflammation are noted. c One month later. Significant
improvement of the ulcerating areas. d At 6 months. The inflammation has subsided, with further improvement of the ulcerating areas. e At one
year. No new ulcers and healed old ones
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Commentary
Autoimmune hepatitis is a chronic self-perpetuating in-
flammatory disease occurring in all ages and races [17].
Besides its diverse presentation and heterogeneity of the
clinical features, AIH is characterized biochemically by el-
evated transaminases, histologically by interface hepatitis,
and serologically by increased levels of immunoglobulin G
(IgG) and autoantibodies, in the absence of viral markers
[17]. Based on the autoantibody profile, two types of AIH
are recognized: type 1 (AIH-1), positive for ANA and/or
anti-smooth muscle antibody (SMA), and occurring at
any age, and type 2 (AIH-2), positive for anti-liver-kidney
microsomal antibody (anti-LKM) or for anti-liver cytosol
type-1 antibody (anti-LC-1), with a peak incidence in chil-
dren and adolescents [17–19]. AIH generally responds to
immunosuppressive treatment, but if left untreated usually
progresses to liver failure requiring transplantation [17].
Extra-hepatic disorders, mainly autoimmune condi-
tions, are common in autoimmune hepatitis and occur
in all stages of liver disease, including ulcerative colitis,
Crohn’s disease, vasculitis, arthritis, thyroiditis, diabetes
mellitus, autoimmune hemolytic anemia, glomeruloneph-
ritis, fibrosing alveolitis, systemic lupus erythematosus,
coeliac disease, sicca syndrome, vitiligo, or lymphoprolifer-
ative syndromes [20, 21].
On the other hand, PG is associated with a variety of
mainly autoimmune diseases in 50–70 % of cases, with in-
flammatory bowel disease (IBD) topping the list at 10–15 %
[6]. However, there is a dearth of data on the association of
PG with AIH, as a search of the English-language literature
unearthed only fifteen other cases [15].
Our patient had AIH-1, as the majority of reported
cases when the type of AIH was identified, although
AIH-2 may be underestimated [15]. Our patient’s gender,
the age at diagnosis of AIH, and the interval to the sub-
sequent onset of PG concur with those of the other re-
ported cases, as does the development of PG during a
quiescent stage of the AIH. Our patient remained in re-
mission subsequently, even with the use of potentially
hepatotoxic agents. Although a fulminant presentation
of AIH has been proposed as a possible risk factor for
the subsequent development of PG [15], our patient’s
hepatitis course was not severe, emphasizing our poor
understanding of the pathogenesis of PG in relation to
AIH. Finally, pathergy, although rare [15], is a hallmark
of PG, and our patient’s first appearance of an ulcer was
Fig. 2 Images of skin biopsy. a Abscess formation in the epidermis (red arrow) with accumulation of neutrophils and granuloma (green arrows)
formation in the dermis. b The edge of an ulcer: deposits of eosinophilic material on the wall of the small blood vessels (blue arrow)
Table 1 Patient’s lab results
Lab test Normal values Result
Hgb (g/dl) 12,0–16,0 12,4
Hct (%) 38–47 37,7
WBC (K/μL) 4,5–11,0 12,300
Neut/Lymph/Mono/Eos (%) 69/25/5/0
PLT (K/μL) 140–440 357
Glu (mg/dl) 74–106 75
Urea (mg/dl) 15–40 25
Creatinine (mg/dl) 0,6–1,1 0,7
AST (U/L) 5–31 13
ALT (U/L) 5–34 11
γGT (U/L) 7–36 12
ALP (U/L) 48–141 59
INR 0,9–1,15 1
HBA1c (%) 4,8–6 5,5
TSH (mU/L) 0,3–4 3
FT4 (pmol/L) 10–25 17
Total Protein (g/dl) 6,4–8,3 7
Albumin (g/dl) 3,5–5,2 4,1
Total Bilirubin (mg/dl) 0,3–1,2 0,47
Direct Bilirubin (mg/dl) 0–0,3 0,14
Sodium (mMol/L) 136–145 144
Potassium (mMol/L) 3,5–5,1 4,2
CRP (mg/dl) 0–5 15,3
ESR (mm) 0–20 38
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at a previously “scratched” area, raising the distinct pos-
sibility of such event.
Conclusion
In summary, we report a patient with autoimmune hepatitis
and pyoderma gangrenosum treated successfully with corti-
sone, cyclosporine, and methotrexate. Thorough testing
excluded concurrent autoimmune diseases, confirming the
association of pyoderma gangrenosum with autoimmune
hepatitis, even when the latter is inactive. Clearly, the diag-
nosis of PG should raise the possibility of concomitant
AIH, since its diagnosis can be challenging and the results
of failure to treat it devastating. On the other hand, AIH
should sensitize us to the possible future development of
PG. Overall, our case adds to the pool of knowledge
about the presentation and management of PG in asso-
ciation with AIH.
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